Cel-Sci Corp. (CVM)
XASE:CVM
Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$0.89 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$14.64M
Enterprise Value$14.18M
Total Cash (Recent Filing)$1.89M
Total Debt (Recent Filing)$8.51M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding14,493,111
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.92
Enterprise Value/Ebitda-0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GMP Contract Manufacturing CapabilityCEL-SCI’s in-house GMP manufacturing and development services provide a durable, non-clinical revenue channel independent of product approval. Long-term, these capabilities can generate milestone and service revenue, deepen customer relationships, and monetize assets while clinical programs mature.
Commercial Partnership In Saudi Arabia (Multikine)A formal distribution and revenue-sharing agreement creates a structural commercialization pathway in a defined market. This reduces go-to-market execution risk, leverages a local partner for regulatory and marketing tasks, and creates a realistic route to sustained regional revenues if regulatory approvals follow.
Moderate Historical LeverageRelative to many early-stage biotech peers, historically moderate leverage gives CEL-SCI greater financial flexibility and lowers default risk. Manageable debt can extend runway and support operational continuity, making it easier to secure financing or absorb shocks while clinical and commercial initiatives advance.
Bears Say
Pre-revenue With Persistent Net LossesBeing pre-revenue with sustained large net losses is a structural weakness: the company cannot self-fund operations from product sales and must rely on external capital. Persistent losses also limit reinvestment, increase dilution risk, and complicate long-term planning absent a clear approval or licensing milestone.
Consistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow creates ongoing runway pressure and forces frequent financing. High and volatile cash burn limits ability to invest in commercialization or scale manufacturing, raises execution risk, and makes strategic planning dependent on market access to capital markets.
Structural Dependence On External FinancingA structural reliance on equity or securities issuance to fund R&D and operations exposes the company to dilution and market-access risk. If capital markets tighten or investor sentiment shifts, the firm may face funding constraints that delay trials, commercialization, or manufacturing expansions.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $14.64M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 59 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on May 18, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.67.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 14,493,111 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20.28%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Technical Analysis
Ownership Overview
4.25% Insiders
2.22% Mutual Funds
0.05% Other Institutional Investors
89.74% Public Companies and
Individual Investors